# US 2017/0254803 A1 · Method for the detection of antigen presentation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0254803 A1
- Document ID: US20170254803A1
- Status: Published application
- Kind: A1
- Application number: 15/519,828
- Filed: 2015-10-22
- Published: 2017-09-07
- Earliest claimed: 2014-10-27
- Assignees: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Applicants: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
- Inventors: Michael PLATTEN; Wolfgang WICK; Lukas BUNSE; Theresa BUNSE; Felix SAHM
- Web page: https://patentgrep.com/patent/US20170254803A1

## CPC

- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/575: for cancer
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- G01N 2333/70539: MHC-molecules, e.g. HLA-molecules
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (MHC) class I or II. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule. The binding agents of the invention are coupled to proximity probes which upon antigen presentation elicit a detectable signal. The method of the invention allows detecting antigen presentation via MHC in-vitro and in a tissue sample in-situ. Thus the method of the present invention finds application as a new diagnostic tool, for example in the diagnosis of various diseases such as infectious diseases, immunological disorders, in particular autoimmune diseases, and proliferative disorders such as cancer.

## Claims

### Claim 1

A method for detecting antigen presentation of an epitope by an antigen presentation molecule, comprising
(a) Providing a first binding agent and a second binding agent, wherein the first binding agent is capable of specifically binding the epitope, and the second binding agent is capable of specifically binding the antigen presentation molecule; wherein the first and the second binding agent are characterized in that spatial proximity of the first binding agent and the second binding agent induces a detectable signal,
(b) Providing an antigen presentation molecule, wherein the antigen presentation molecule is suspected of presenting the epitope,
(c) Providing the epitope,
(d) Bringing into contact the epitope, the antigen presentation molecule, the first binding agent and the second binding agent,
wherein the presence of the detectable signal is indicative for the antigen presentation of the epitope by the antigen presentation molecule.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the first binding agent comprises a first proximity probe and the second binding agent comprises a second proximity probe, wherein spatial proximity of the first proximity probe and the second proximity probe induces the detectable signal.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising providing a third binding agent capable of specifically binding to the first binding agent; providing a fourth binding agent capable of specifically binding to the second binding agent; and wherein step (d) comprises bringing into contact the epitope, the antigen presentation molecule, the first binding agent, the second binding agent, the third binding agent, and the fourth binding agent.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the third binding agent comprises a first proximity probe and the fourth binding agent comprises a second proximity probe, wherein spatial proximity of the first proximity probe and second proximity probe induces the detectable signal.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the binding agents are monoclonal- or polyclonal antibodies, preferably monoclonal antibodies.

### Claim 6 (depends on 1)

The method according to claim 1, wherein in step (b) the antigen presentation molecule is provided in a biological cell, preferably on the surface on a biological cell such as an antigen presenting cell selected from a dendritic cell, a B lymphocyte or a tumor cell.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the epitope is a disease associated antigen, preferably an epitope associated with an immunological disorder, such as an autoimmune disorder, or a tumor associated antigen (TAA), or an epitope derived from a TAA, preferably wherein the TAA is selected from the group of cancer mutated antigens, cancer germ line expressed antigens, cancer viral antigens or cancer overexpression antigens.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the epitope is derived from IDH1 and comprises the IDH1R132H mutation, most preferably a peptide comprising an amino acid sequence according to SEQ ID NO: 30 (peptide IDH1R132H p125-137), or wherein the epitope is derived from NY-ESO-1.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the epitope is provided by providing a biological cell expressing the epitope or a precursor thereof; or alternatively ectopically expressing the epitope, or a precursor thereof, in a biological cell, preferably a cell which further comprises the antigen presentation molecule, most preferably an antigen presenting cell such as a dendritic cell, a B lymphocyte or a tumor cell.

### Claim 10 (depends on 1)

A method for generating a personalized disease therapy plan for treating a subject suffering from a disease, the method comprising the steps of
(a) Providing a biological sample obtained from the subject,
(b) Detecting antigen presentation of at least one known epitope or antigen in the biological sample using the method according to claim 1, wherein the epitope and the antigen presentation molecule are provided in the biological sample, and
(c) Generating a therapy plan for treating the subject by selecting a vaccine composition comprising vaccine-molecules corresponding to the epitope or antigen as detected in (a).

### Claim 11 (depends on 1)

A method for producing a personalized vaccine composition, the method comprising the steps of
(a) Providing a biological sample obtained from the subject,
(b) Detecting antigen presentation of at least one known epitope or antigen in the biological sample using the method according to claim 1, wherein the epitope and the antigen presentation molecule are provided in the biological sample, and
(c) Producing a personalized vaccine composition by admixing vaccine compounds into a composition which correspond to the epitopes/antigens as detected in (b).

### Claim 12 (depends on 10)

The method according to claim 10, wherein the biological sample is a tissue sample, and the detecting antigen presentation is performed in the tissue sample in-situ.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the epitope is, or is derived of, a TAA, preferably a mutated tumor antigen.

### Claim 14 (depends on 1)

A method for diagnosing, stratifying, monitoring or classifying a subject suffering from a disease, the method comprising the steps of:
(e) Providing a biological sample of the subject suffering from a disease to be diagnosed,
(f) Detecting antigen presentation of at least one known epitope or antigen in the biological sample, the epitope being characteristic for a candidate disease, using the method according to claim 1, wherein the epitope and the antigen presentation molecule are provided in the biological sample,
wherein a diagnosis is provided based on the presence or absence of the presentation of the epitope/antigen in said cellular sample or tissue sample.

### Claim at position 15

-17. (canceled)

### Claim 18

A proximity ligation assay (PLA) kit for detecting antigen presentation of an epitope by an antigen presentation molecule, said PLA kit comprising: a first binding agent and a second binding agent, wherein the first binding agent is capable of specifically binding the epitope, and the second binding agent is capable of specifically binding the antigen presentation molecule; wherein the first and the second binding agent are characterized in that spatial proximity of the first binding agent and the second binding agent induces a detectable signal.

### Claim 19 (depends on 18)

The PLA kit according to claim 18, wherein the first binding agent comprises a first proximity probe and the second binding agent comprises a second proximity probe, wherein spatial proximity of the first proximity probe and the second proximity probe induces the detectable signal.

### Claim 20 (depends on 18)

The PLA kit according to claim 18, further comprising: a third binding agent capable of specifically binding to the first binding agent and a fourth binding agent capable of specifically binding to the second binding agent.

### Claim 21 (depends on 20)

The PLA kit according to claim 20, wherein the third binding agent comprises a first proximity probe and the fourth binding agent comprises a second proximity probe, wherein spatial proximity of the first proximity probe and second proximity probe induces the detectable signal.
